SEC Comment Letter for ELITE PHARMACEUTICALS (ELTP) — May 2, 2008

ELITE PHARMACEUTICALS INC /NV/ (ELTP) (CIK 0001053369)
Date: May 2, 2008 · CIK: 0001053369 · Accession: 0000000000-08-022896

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

May 2, 2008

Author

Jeffrey Riedler

Form

UPLOAD

Company

ELITE PHARMACEUTICALS INC /NV/ (ELTP) (CIK 0001053369)

Letter

Mail Stop 6010 May 2, 2008 Mr. Mark I. Gittleman Chief Financial Officer and Secretary Elite Pharmaceuticals, Inc. 165 Ludlow Avenue Northvale, New Jersey 07647 Re: Elite Pharmaceuticals, Inc. Revised preliminary proxy statement filed May 2, 2008 File No. 1-10581 Dear Mr. Gittleman: We have completed our review of your preliminary proxy statement and related filings and have no further comments at this time. S i n c e r e l y , J e f f r e y R i e d l e r A s s i s t a n t D i r e c t o r cc: Scott H. Rosenblatt, Esquire Reitler Brown & Rosenblatt LLC 800 Third Avenue, 21 st Floor New York, New York 10022-7604

Show Raw Text

Mail Stop 6010      May 2, 2008     Mr. Mark I. Gittleman Chief Financial Officer and Secretary Elite Pharmaceuticals, Inc. 165 Ludlow Avenue Northvale, New Jersey 07647
Re: Elite Pharmaceuticals, Inc.
Revised preliminary proxy statement filed May 2, 2008
File No. 1-10581
 Dear Mr. Gittleman:   We have completed our review of your  preliminary proxy statement and related
filings and have no further comments at this time.
        S i n c e r e l y ,
          J e f f r e y  R i e d l e r          A s s i s t a n t  D i r e c t o r           cc: Scott H. Rosenblatt, Esquire      Reitler Brown & Rosenblatt LLC      800 Third Avenue, 21
st Floor
     New York, New York 10022-7604

SecProbe.io